A surgeon in London has carried out what is being described as the United Kingdom’s first long-distance robotic operation on a patient located ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

For more information about Candel, visit: www.candeltx.com.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Testosterone cream is a needle-free testosterone therapy ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

Lantheus said that the FDA approved its PYLARIFY TruVu injection.

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing ...